Skip to main content

Table 4 Adverse events "likely" or "definitely" related to study treatment

From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

System organ class

Preferred term

Synvisc-one n = 32

Hydros n = 32

Hydros-TA n = 34

Musculoskeletal and Connective Tissue disorders, n (%)

Arthralgia

5 (16)

4 (13)

1 (3)

Joint Stiffness

2 (6)

2 (6)

0

Joint Swelling

1 (3)

0

0

General Disorders and Administration Site conditions, n (%)

Application Site Warmth

1 (3)

0

0

Injection Site Warmth

0

0

1 (3)

Injection Site Movement Impairment

0

1 (3)

0

Injection site pain

0

0

1 (3)

Total Related Adverse Events,

n (%)

NA

9 (28)

7 (22)

3 (9)